233 related articles for article (PubMed ID: 25796537)
1. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
Ali SM; Stephens PJ; Miller VA; Ross JS; Pal SK
Eur Urol; 2015 Aug; 68(2):341-3. PubMed ID: 25796537
[No Abstract] [Full Text] [Related]
2. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors.
Bukowski RM
Clin Genitourin Cancer; 2007 Sep; 5(6):359-61. PubMed ID: 17956708
[No Abstract] [Full Text] [Related]
3. Selective Efficacy of Temsirolimus on Bone Metastases in Chromophobe Renal Cell Carcinoma.
Huelsmann L; Kim DNW; Hannan R; Watumull LM; Brugarolas J
Clin Genitourin Cancer; 2015 Aug; 13(4):e321-e323. PubMed ID: 25620636
[No Abstract] [Full Text] [Related]
4. Flcn-deficient renal cells are tumorigenic and sensitive to mTOR suppression.
Wu M; Si S; Li Y; Schoen S; Xiao GQ; Li X; Teh BT; Wu G; Chen J
Oncotarget; 2015 Oct; 6(32):32761-73. PubMed ID: 26418749
[TBL] [Abstract][Full Text] [Related]
5. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
6. mTOR pathway inhibition in renal cell carcinoma.
Pinto Marín A; Redondo Sánchez A; Espinosa Arranz E; Zamora Auñón P; Castelo Fernández B; González Barón M
Urol Oncol; 2012; 30(4):356-61. PubMed ID: 20207176
[TBL] [Abstract][Full Text] [Related]
7. Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus.
Cetin B; Coskun U; Yildiz R; Buyukberber S; Baykara M; Benekli M
J Oncol Pharm Pract; 2011 Sep; 17(3):274-8. PubMed ID: 20215482
[TBL] [Abstract][Full Text] [Related]
8. Everolimus for the treatment of advanced renal cell carcinoma.
Amato R
Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
[TBL] [Abstract][Full Text] [Related]
9. Everolimus in renal cell carcinoma.
Wang Y
Drugs Today (Barc); 2010 Aug; 46(8):557-66. PubMed ID: 20830316
[TBL] [Abstract][Full Text] [Related]
10. mTOR-inhibition in metastatic renal cell carcinoma. Focus on temsirolimus: a review.
Gerullis H; Ecke TH; Eimer C; Heuck CJ; Otto T
Minerva Urol Nefrol; 2010 Dec; 62(4):411-23. PubMed ID: 20944541
[TBL] [Abstract][Full Text] [Related]
11. Temsirolimus (Torisel) for advanced renal cell carcinoma.
Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154
[No Abstract] [Full Text] [Related]
12. Response to crizotinib in a patient with MET-mutant papillary renal cell cancer after progression on tivantinib.
Stein MN; Hirshfield KM; Zhong H; Singer EA; Ali SM; Ganesan S
Eur Urol; 2015 Feb; 67(2):353-4. PubMed ID: 25457019
[No Abstract] [Full Text] [Related]
13. mTOR inhibition in advanced renal cell carcinoma: which criteria should be used to evaluate therapeutic outcome?
Eimer C; Gerullis H; Heuck C; Otto T
Anticancer Drugs; 2011 Jan; 22(1):18-23. PubMed ID: 21037468
[TBL] [Abstract][Full Text] [Related]
14. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
[TBL] [Abstract][Full Text] [Related]
15. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
Danesi R; Boni JP; Ravaud A
Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
[TBL] [Abstract][Full Text] [Related]
16. [Role of mTOR inhibition in the treatment of metastatic renal cell carcinoma].
Mizuno R; Miyajima A; Oya M
Nihon Jinzo Gakkai Shi; 2012; 54(5):581-5. PubMed ID: 22991836
[No Abstract] [Full Text] [Related]
17. Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma.
Hamieh L; Choueiri TK; Ogórek B; Khabibullin D; Rosebrock D; Livitz D; Fay A; Pignon JC; McDermott DF; Agarwal N; Gao W; Signoretti S; Kwiatkowski DJ
PLoS Genet; 2018 Sep; 14(9):e1007679. PubMed ID: 30256787
[TBL] [Abstract][Full Text] [Related]
18. [Metastatic renal cell carcinoma treated with everolimus--data from the RENIS Clinical Registry].
Büchler T; Dusek L; Fínek J; Poprach A; Budnáková D; Kandrnal V; Jarkovský J; Bortlícek Z; Klimes D; Abrahámová J; Vyzula R
Klin Onkol; 2011; 24(5):389-92. PubMed ID: 22070021
[TBL] [Abstract][Full Text] [Related]
19. Re: Camillo Porta, Emiliano Calvo, Miguel A. Climent, et al. Efficacy and safety of everolimus in elderly patients with metastatic renal cell carcinoma: an exploratory analysis of the outcomes of elderly patients in the RECORD-1 Trial. Eur Urol 2012;61:826-33.
Procopio G; Verzoni E; De Braud F
Eur Urol; 2012 Jul; 62(1):e5-6; author reply e7-8. PubMed ID: 22487015
[No Abstract] [Full Text] [Related]
20. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma.
Cho D; Signoretti S; Dabora S; Regan M; Seeley A; Mariotti M; Youmans A; Polivy A; Mandato L; McDermott D; Stanbridge E; Atkins M
Clin Genitourin Cancer; 2007 Sep; 5(6):379-85. PubMed ID: 17956710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
